Fused Tricyclic Compounds as novel mTOR inhibitors

US8609675B2 · kind B2 · utility

Assignee

• Merck Sharp & Dohme LLC · US

Inventors

• Cliff C. Cheng · Cambridge, US
• Hongbo Zeng · Westford, US
• Gerald W. Shipps, Jr. · Stoneham, US
• Yongqi Deng · Newton, US
• Zhaoyang Meng · Ambler, US
• Lianyun Zhao · Burlington, US
• Yang Nan · Nanjing, CN
• Binyuan Sun · Sharon, US
• Duan Liu · Arlington, US
• Panduranga Adulla P. Reddy · Walpole, US
• M. Arshad Siddiqui · Newton, US

Key dates

• Filing date: Jun 30, 2010
• Grant date: Dec 17, 2013
• Expiry date: Jun 30, 2030

Classification

• Technology area (CPC A): Human Necessities
• CPC primary: A61P35/00
• WIPO field: Organic fine chemistry
• WIPO sector: Chemistry

Abstract

The present invention provides Fused Tricyclic Compounds of the Formula (I) wherein Q, R1, R2, R3, and R4 are as defined herein, and pharmaceutically acceptable salts of such Fused Tricyclic Compounds. The Fused Tricyclic Compounds are useful in the treatment of cancer and other proliferative disorders.